ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Ash Stevens To Make Ariad Drug

by Ann M. Thayer
June 17, 2013 | APPEARED IN VOLUME 91, ISSUE 24

Ash Stevens, a Riverview, Mich.-based contract manufacturer, is making the active pharmaceutical ingredient for Ariad Pharmaceuticals’ leukemia drug Iclusig (ponatinib). FDA approved the drug in December 2012 and recently signed off on Ash Stevens’ production process, which incorporates quality-by-design principles. The drug is the first that Ariad developed and commercialized on its own. The drug marks Ash Stevens’ 12th manufacturing approval for a new chemical entity.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment